Home/Pipeline/SPY130

SPY130

Ulcerative Colitis (UC)

Phase 1Active; Phase 2 initiation expected after Part A (mono open-label)

Key Facts

Indication

Ulcerative Colitis (UC)

Phase

Phase 1

Status

Active; Phase 2 initiation expected after Part A (mono open-label)

Company

Spyre Therapeutics

About Spyre Therapeutics

Spyre Therapeutics is pioneering a novel approach to treating IBD and rheumatological diseases by developing engineered antibodies designed for prolonged activity and convenient, infrequent dosing. Its core strategy involves targeting well-validated pathways—α4β7, TL1A, and IL-23—both as monotherapies and in innovative combinations, with the goal of achieving deeper remission for patients. The company is advancing a robust pipeline through its Phase 2 SKYLINE-UC trial and has built a leadership team with extensive experience in drug development and commercialization. Spyre's vision is to overcome the limitations of current therapies, such as low remission rates and frequent injections, by delivering superior efficacy and improved patient compliance.

View full company profile

Therapeutic Areas

Gastroenterology Rheumatology Immunology

Other Ulcerative Colitis (UC) Drugs

Drug	Company	Phase	Status
SPY001	Spyre Therapeutics	Phase 2	Active; Part A topline expected Q2 2026
SPY002	Spyre Therapeutics	Phase 2	Active; Phase 2 initiated
SPY003	Spyre Therapeutics	Phase 2	Active; Phase 2 initiated
SPY120	Spyre Therapeutics	Phase 1	Active; Phase 2 initiation expected after Part A (mono open-label)
SPY230	Spyre Therapeutics	Phase 1	Active; Phase 2 initiation expected after Part A (mono open-label)
Vidofludimus calcium (IMU-838)	Immunic	Phase 2	Active